文献速递眼底病与葡萄膜炎

阿达木单抗治疗非感染性葡萄膜炎患者的安全性与疗效:正在进行的开放标签研究VISUAL III

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
PubMed 文献 · Ophthalmology · 2018-02-09

VISUAL III为3期开放标签多中心延伸研究,评估阿达木单抗40 mg每两周一次治疗非感染性中间、后或全葡萄膜炎。纳入424例患者中371例进入意向治疗分析,活动性葡萄膜炎患者第78周60%达疾病静止、66%停用糖皮质激素,视力改善且激素剂量降低,未发现新安全性信号。

要点

  • 活动性葡萄膜炎患者第78周60%(145/242,无应答者填补)达疾病静止,其中66%(95/143,观测分析)停用糖皮质激素。
  • 非活动性葡萄膜炎患者第78周74%(96/129)维持静止,93%(89/96)停用糖皮质激素且激素剂量未增加。
  • 活动性葡萄膜炎患者最佳矫正视力从0.27改善至0.14 logMAR,平均激素剂量从13.6 mg/天降至2.6 mg/天。

核心结论

  • 研究开始时活动性葡萄膜炎患者接受阿达木单抗治疗可能达到疾病静止、改善视力并减少每日全身糖皮质激素用量。
  • 研究开始时非活动性葡萄膜炎患者多数维持疾病静止且全身糖皮质激素剂量未增加。
  • 未发现新的安全性信号。

研究设计与样本

  • 3期、开放标签、多中心临床试验延伸研究(VISUAL III)。
  • 纳入符合治疗失败标准或完成VISUAL I或II且未治疗失败的成人患者。
  • 患者接受阿达木单抗40 mg每两周一次,描述VISUAL III第0至78周的中期随访数据。
  • 424例患者入组,371例纳入意向治疗分析。

主要发现

  • 研究开始时242/371(65%)患者有活动性葡萄膜炎,第78周60%(145/242,无应答者填补)达到疾病静止,其中66%(95/143,观测分析)停用糖皮质激素。
  • 研究开始时129/371(35%)患者为非活动性葡萄膜炎,第78周74%(96/129,无应答者填补)达到疾病静止,其中93%(89/96,观测分析)停用糖皮质激素。
  • 活动性葡萄膜炎患者的炎症性脉络膜视网膜/视网膜血管病变、前房细胞分级和玻璃体混浊分级显示初期改善后下降,非活动性葡萄膜炎患者保持稳定。
  • 活动性葡萄膜炎患者最佳矫正视力从第0周至第78周改善(0.27至0.14 logMAR;左右眼;观测分析),非活动性葡萄膜炎患者保持稳定。
  • 活动性葡萄膜炎患者平均糖皮质激素剂量从13.6 mg/天(第0周)降至2.6 mg/天(第78周),非活动性葡萄膜炎患者保持稳定(1.5-1.2 mg/天)。

关键数值与推荐

  • 疾病静止和停用糖皮质激素比例采用无应答者填补和观测分析报告。
  • 连续数据采用末次观测值结转和观测分析报告,糖皮质激素剂量采用观测病例分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Phase 3, open-label, multicenter clinical trial extension (VISUAL III). PARTICIPANTS: Adults meeting treatment failure (TF) criteria or who completed VISUAL I or II (phase 3, randomized, double-masked, placebo-controlled) without TF. METHODS: Patients received adalimumab 40 mg every other week. Interim follow-up data were described from VISUAL III weeks 0 through 78. MAIN OUTCOME MEASURES: Disease quiescence, steroid-free quiescence, active inflammatory chorioretinal/retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, best-corrected visual acuity (BCVA), and corticosteroid dose. Binary data were reported using nonresponder imputation (NRI), continuous data using last observation carried forward and as-observed analysis, and corticosteroid dose using observed-case analysis. Adverse events (AEs) were reported from first adalimumab dose in VISUAL III through interim cutoff. RESULTS: Of 424 patients enrolled, 371 were included in intent-to-treat analysis. At study entry, 242 of 371 (65%) patients had active uveitis; 60% (145/242, NRI) achieved quiescence at week 78, and 66% (95/143, as-observed) of those were corticosteroid free. At study entry, 129 of 371 (35%) patients had inactive uveitis; 74% (96/129, NRI) achieved quiescence at week 78, and 93% (89/96, as-observed) of those were corticosteroid free. Inflammatory lesions, anterior chamber grade, and vitreous haze grade showed initial improvement followed by decline in patients with active uveitis and remained stable in patients with inactive uveitis. BCVA improved in patients with active uveitis from weeks 0 to 78 (0.27 to 0.14 logMAR; left and right eyes; as-observed) and remained stable in patients with inactive uveitis. Mean corticosteroid dose decreased from 13.6 mg/day (week 0) to 2.6 mg/day (week 78) in patients with active uveitis and remained stable in those with inactive uveitis (1.5-1.2 mg/day). AEs (424 events/100 patient-years) and serious AEs (16.5 events/100 patient-years) were comparable with previous VISUAL trials. CONCLUSIONS: Patients with active uveitis at study entry who received adalimumab therapy were likely to achieve quiescence, improve visual acuity, and reduce their daily uveitis-related systemic corticosteroid use. Most patients with inactive uveitis at study entry sustained quiescence without a systemic corticosteroid dose increase. No new safety signals were identified.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Suhler EB, Adán A, Brézin AP, et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018. PMID: 29429764. doi:10.1016/j.ophtha.2017.12.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。